Secretory phospholipases A 2 (sPLA 2 s) represent a rapidly expanding family of structurally related enzymes found in mammals as well as in insect and snake venoms. In this report, a cDNA coding for a novel sPLA 2 has been isolated from human fetal lung, and its gene has been mapped to chromosome 16p13.1-p12. The mature sPLA 2 protein has a molecular mass of 13.6 kDa, is acidic (pI 5.3), and made up of 123 amino acids. Key structural features of the sPLA 2 include: (i) a long prepropeptide ending with an arginine doublet, (ii) 16 cysteines located at positions that are characteristic of both group I and group II sPLA 2 s, (iii) a C-terminal extension typical of group II sPLA 2 s, (iv) and the absence of elapid and pancreatic loops that are characteristic of group I sPLA 2 s. Based on these structural properties, this sPLA 2 appears as a first member of a new group of sPLA 2 s, called group X. A 1.5-kilobase transcript coding for the human group X (hGX) sPLA 2 was found in spleen, thymus, and peripheral blood leukocytes, while a less abundant 0.8-kilobase transcript was detected in the pancreas, lung, and colon. When the hGX sPLA 2 cDNA was expressed in COS cells, sPLA 2 activity preferentially accumulated in the culture medium, indicating that hGX sPLA 2 is an actively secreted enzyme. It is maximally active at physiological pH and with 10 mM Ca 2؉ . hGX sPLA 2 prefers phosphatidylethanolamine and phosphatidylcholine liposomes to those of phosphatidylserine.
dins, hydroxy fatty acids, leukotrienes, thromboxanes, and platelet-activating factor. Over the last two decades, two major classes of mammalian PLA 2 s (intracellular and secretory) have been characterized and cloned. Secretory PLA 2 s were first characterized and then classified into different groups according to their molecular structure and the localization of their disulfide bridges (4, 5) . Recently, an updated classification of PLA 2 s has been proposed that include both intracellular and secretory types of PLA 2 s (2) . A number of intracellular PLA 2 s have been characterized and now comprise the well known Ca 2ϩ -sensitive arachidonoyl-specific 85-kDa cPLA 2 (6, 7) , multiple Ca 2ϩ -independent PLA 2 s (1, 2, 8) as well as several other types of cytosolic enzymes less extensively characterized (9 -13) .
Secretory low molecular mass PLA 2 s (sPLA 2 s, 13-18 kDa) form a class of structurally related enzymes whose members are also rapidly increasing (2) . These enzymes are characterized by the presence of several disulfide bridges, an absolute catalytic requirement for millimolar concentration of Ca 2ϩ , and a broad specificity for phospholipids with different polar head groups and fatty acyl chains (14) . sPLA 2 s have been purified from a variety of sources including not only mammalian pancreas, spleen, lung, platelets, and extracellular fluids, but also insect and snake venoms (1, (15) (16) (17) . Pancreatic sPLA 2 , nonpancreatic inflammatory sPLA 2 , bee venom sPLA 2 , and a novel sPLA 2 highly expressed in heart, are prototypes of group I, II, III, and V, respectively (2) . The pancreatic group I sPLA 2 , as its name indicates, was originally purified from pancreatic juice and then identified and cloned in other tissues, such as lung, spleen, kidney, and ovary (3, 18 -20) . Besides its primary function in digestion of dietary lipids, the pancreatic group I sPLA 2 has been proposed to play a role in cell proliferation (21) , smooth muscle contraction (22, 23) , as well as acute lung injury (24) . The inflammatory group II sPLA 2 (initially called nonpancreatic sPLA 2 ) has been purified and cloned from various sources, including platelets and extracellular fluids (16, 25, 26) . It is highly expressed in the plasma and synovial fluids of patients with various inflammatory diseases, such as rheumatoid arthritis, acute pancreatitis, Crohn's disease, and in endotoxic shock (27) (28) (29) (30) (31) , as well as in various gastrointestinal cancers (32, 33) . It is considered as a potent mediator of the inflammatory process (16, 27, 29, 30, 34) and has been recently proposed as a tumor suppressor gene of intestinal tumorigenesis (35) . The human group V sPLA 2 has been cloned from brain and is found strongly expressed in heart (36, 37) . More recently, this sPLA 2 has been detected in P388D1 murine macrophages where it may act as a novel sPLA 2 effector involved in lipid mediators production (38) . A fourth sPLA 2 has been cloned in rat and mouse (39) , but appears to be a nonfunctional pseudogene in humans (40) . This sPLA 2 belongs to group IIC and is prevalently expressed in testis. Other low molecular mass PLA 2 s have been characterized from various tissues including spermatozoa, brain, and lung, suggesting a larger diversity of PLA 2 s (41) (42) (43) (44) . Moreover, a sPLA 2 -related gene has been cloned from human teratocarcinoma cells and found to code for a protein of 689 amino acids containing two domains of high homology with sPLA 2 s (45) .
A wealth of sPLA 2 s have also been described in snake and insect venoms. Besides a role in prey digestion, several venom sPLA 2 s are potent toxins that display neurotoxicity and myotoxicity among a variety of other toxic effects (17, 46, 47) . Studies with several iodinated venom sPLA 2 s, including OS 1 and OS 2 purified from Taipan snake venom, have shown the existence of various high affinity sPLA 2 receptors (48) . N-type sPLA 2 receptors were first identified in rat brain membranes and are made up of several protein subunits of 36 -51 kDa and 85 kDa (49) . These receptors display a high affinity for neurotoxic sPLA 2 s, but not for nontoxic sPLA 2 s, suggesting that N-type receptors may contribute to sPLA 2 neurotoxic effects (49 -51) . M-type sPLA 2 receptors were first identified in skeletal muscle cells (52) . They consist of a single 180-kDa subunit and bind a number of toxic and nontoxic venom sPLA 2 s. The M-type sPLA 2 receptor has now been cloned in various species (53) (54) (55) (56) , and its molecular properties have been analyzed in detail (57) (58) (59) (60) (61) . Although the physiological roles of M-and Ntype receptors remain to be discovered, M-type receptors from various species have been shown to associate with high affinity pancreatic group I sPLA 2 s as well as inflammatory group II sPLA 2 s with K d values of 1-10 nM, suggesting that mammalian endogenous sPLA 2 s might be the natural ligands of these receptors (21, 48, 54, 61) .
We now report the cloning, chromosomal mapping, and recombinant expression of a novel human sPLA 2 . Based on its structural properties, this sPLA 2 appears as a first member of a new group of mammalian sPLA 2 s, called group X, according to the PLA 2 nomenclature defined recently (2).
EXPERIMENTAL PROCEDURES
Identification of the 309343 3Ј Expressed Sequence Tag (EST) Sequence-Protein sequences of different sPLA 2 s were used to search for homologues in gene data bases stored at the National Center for Biotechnology (NCBI) by using the tBLASTn sequence alignment program (62) . Translation of an EST sequence (I.M.A.G.E. Consortium clone identification 309343, 3Ј, GenBank TM accession no. N93958) (63) in one frame presented a significant sequence similarity (p ϭ 9.9 e Ϫ21 ) with several sPLA 2 s. This 445-bp sequence was originally obtained from a human fetal lung cDNA library. A 327-bp DNA fragment corresponding to the EST sequence was then amplified by reverse transcriptase-PCR using human fetal lung cDNA. For that purpose, poly(A) ϩ mRNA (CLONTECH Laboratories, Inc.) was reverse-transcribed with the Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc.) according to the manufacturer's protocol and used for PCR with a sense primer (5Ј-GGAATTCGCCTATATGAAATATGGT-3Ј) and an antisense primer (5Ј-GGAATTCAAGGTAGTCAGTCACACTTG-3Ј) containing EcoRI restriction sites. PCR reactions were performed using a low error rate DNA polymerase (PWO polymerase, Eurogentec Corp., Belgium) in a total volume of 50 l containing 10 mM Tris-HCl, pH 8.85, 25 mM KCl, 2.0 mM MgCl 2 , 200 M dNTPs, 200 M of each primer, 20 ng of cDNA template, and 1 unit of PWO DNA polymerase. PCR conditions were: 94°C, 30 s; 50°C, 30 s, and 72°C, 30 s, for 33 cycles. The 327-bp DNA fragment was then subcloned into pBlueScript (Stratagene Cloning Systems) and sequenced to verify its identity with the EST sequence by using an automatic sequencer (Applied Biosystems model 373A) with the dideoxy nucleotide method.
Chromosomal Mapping of the hGX sPLA 2 Gene-In situ hybridization was performed on chromosome preparations obtained from phytohemagglutinin-stimulated human lymphocytes cultured for 72 h. 5-Bromodeoxyuridine (60 g/ml) was added for the final 7 h of culture to ensure a posthybridization chromosomal banding of good quality. The 5Ј Alu repeat element was removed from the full-length hGX sPLA 2 cDNA clone by restriction with ApoI, and the resulting DNA fragment (nucleotides Ϫ370 to 580, see Fig. 1 ) inserted into pBlueScript was tritium-labeled by nick-translation to a specific activity of 10 8 dpm/g. The radiolabeled probe was hybridized to metaphase spreads at a final concentration of 200 ng/ml of hybridization solution as described previously (64) . After coating with nuclear track emulsion (Kodak NTB 2 ), slides were exposed for 20 days at 4°C and then developed. To avoid any slipping of silver grains during the banding procedure, chromosome spreads were first stained with buffered Giemsa solution and metaphase-photographed. R-banding was then performed by the fluorochrome-photolysis-Giemsa method, and metaphases were rephotographed before analysis.
Northern Blot Analysis-Three human multiple tissue Northern blots (CLONTECH Laboratories, Inc., catalog nos. 7759-1, 7760-1, and 7770-1) were first probed with the randomly primed 32 P-labeled PCR fragment corresponding to a partial sequence of hGX sPLA 2 cDNA (nucleotide 179 -507 in Fig. 1 ) in 50% formamide, 5 ϫ SSPE (0.9 M NaCl, 50 mM sodium phosphate, pH 7.4, 5 mM EDTA), 5 ϫ Denhardt's solution, 0.1% SDS, 20 mM sodium phosphate, pH 6.5, and 250 g/ml denatured salmon sperm DNA at 42°C for 18 h. Blots were washed to a final stringency of 0.1 ϫ SSC (30 mM NaCl, 3 mM trisodium citrate, pH 7.0) with 0.1% SDS at 55°C and then exposed to Kodak X-Omat AR films with two intensifying screens. Northern blots were then stripped and hybridized in the same conditions as above with the entire coding sequences of the human group V sPLA 2 (36), the human group II sPLA 2 (25) , the human group I sPLA 2 (19) , and finally with the manufacturersupplied ␤-actin probe.
Expression of hGX sPLA 2 in COS and HEK 293 Cells-The fulllength 1020-bp cDNA clone coding for hGX sPLA 2 was subcloned directly into the expression vector pcDNA I (Invitrogen Corp.) by using convenient restriction enzyme sites. hGX sPLA 2 clones Met-42 and Met-32 were prepared by a PCR-assisted strategy using a low error rate PWO DNA polymerase (Eurogentec Corp., Belgium) and respective sense oligonucleotides primers (Met-42, 5Ј-GGAATTCGCGGCCGCCA-TGGGGCCGCTACCTGTGT-3Ј; Met-32, 5Ј-GGAATTCGCGGCCGCCA-TGCTGCTCCTGCTACTGC-3Ј) in combination with a common antisense oligonucleotide (5Ј-GTCTAGAGTCAGTCACACTTGGGCGAGT--3Ј). Primers contained restriction sites to facilitate subcloning of the PCR fragments and consensus Kozak sequences were added to the sense primers to enhance protein expression (65) . The PCR products were subcloned into pcDNA I and sequenced to verify the integrity of DNA constructions. The various plasmids were then transfected into COS or HEK 293 cells by a modification of the DEAE-dextran/chloroquine method (66) or by the Ca/PO 4 procedure (67), respectively. Cells at 50% confluence were transfected with 5 g of plasmid DNA/75-cm 2 Petri dish. Cell supernatants were harvested at different times post transfection and assayed for hGX sPLA 2 activity. On day 3, washed cells were harvested and disrupted by sonication in 300 l of 20 mM Tris-HCl, pH 7.4, 2 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride to measure cell-associated sPLA 2 activity. To test whether hGX sPLA 2 is secreted as a proenzyme, serum-free cell supernatants containing hGX sPLA 2 activity were treated with 3 g/ml trypsin (Sigma, T-1005 type XI from bovine brain) in 20 mM Tris-HCl, pH 8.0, 10 mM CaCl 2 for 3 h at 37°C and then assayed for sPLA 2 2 assays were performed essentially as described previously (57) . Unless otherwise specified, sPLA 2 assays were performed at 25°C in a total volume of 100 l consisting of 140 mM NaCl, 50 mM Tris-HCl, pH 7.4, 10 mM CaCl 2 , 0.1% bovine serum albumin, and 100,000 dpm of [ 3 H]oleatelabeled E. coli membranes. Incubation times and sample volumes were adjusted to ensure hydrolysis rates within the linear range of enzymatic assays. Typically, 3-10 l of solution containing hGX sPLA 2 were incubated for 30 -60 min at 20°C to measure sPLA 2 activity. Reaction mixtures were stopped by adding 300 l of 0.1 M EDTA, pH 8.0, and 1% fatty acid-free bovine serum albumin. After centrifugation at 10,000 ϫ g for 3 min, 300 l of supernatant containing hydrolyzed phospholipids were counted. Control incubations in the absence of added sPLA 2 were carried out in parallel and used to calculate specific hydrolysis.
sPLA 2 Activity Assay on Mixed Phospholipid Liposomes-Liposomes were prepared by sonication using different phospholipid mixtures (phosphatidylethanolamine, phosphatidylcholine, or phosphatidylserine, with D-␣-dipalmitoylphosphatidylcholine, 75:25 mol%). D-␣-Dipalmitoylphosphatidylcholine is a nonhydrolyzable phospholipid that is used for formation of liposomes with the various hydrolyzable phospholipids. L-␣-Phosphatidylcholine (from egg yolk), L-␣-phosphatidylethanolamine (from egg yolk), L-␣-phosphatidylserine (from bovine brain), and D-␣-dipalmitoylphosphatidylcholine were purchased from Sigma.
Phospholipids were dissolved in chloroform, dried under a nitrogen stream, and resuspended at 0.33 mM in 100 mM Tris-HCl buffer, pH 7.4. The lipid suspension was then sonicated twice for 2 min with a 20-kHz MSE tip probe at 100 W. Incubations were carried out for 15 min at 37°C in a total volume of 500 l containing 200 nmol of hydrolyzable phospholipids resuspended in 100 mM Tris-HCl, pH 7.4, 10 mM CaCl 2 , and 0.1% fatty acid-free BSA. hGX sPLA 2 activity was measured by adding 20 l of a 72-h COS cell supernatant, and incubation was carried out for 15 min at 37°C. Released fatty acids were extracted by a modification of Dole's procedure (68) , methylated with diazomethane, and quantified as described below by GC-MS measurements. Control incubations in the absence of added sPLA 2 were carried out in parallel and used to calculate specific hydrolysis.
sPLA 2 Activity Assay on Erythrocyte Membrane Phospholipids-Human erythrocytes were isolated from fresh citrated blood by the procedure of Steck et al. (69) . Briefly, blood was centrifuged for 10 min at 4°C at 100 ϫ g. Red blood cells were then collected, washed several times with 5 volumes of an ice-cold phosphate saline buffer (150 mM NaCl, 5 mM sodium phosphate, pH 8.0), and hemolyzed in 40 volumes of 5 mM sodium phosphate, pH 8.0. Erythrocyte ghosts were collected by centrifugation for 20 min at 22,000 ϫ g and washed several times with 5 mM phosphate buffer until "white ghosts" were obtained. sPLA 2 assays were performed in a total volume of 500 l containing erythrocyte membranes (representing 200 nmol of hydrolyzable phospholipids) resuspended in 100 mM Tris-HCl, pH 7.4, 10 mM CaCl 2 , and 0.1% fatty acid-free bovine serum albumin. Incubations were carried out for 15 min at 37°C with translational shaking. 20 l of a 72-h COS cell supernatant were used to measure hGX sPLA 2 activity. The released fatty acids were extracted by a modification of the Dole's procedure (68), methylated with diazomethane, and quantified by GC-MS measurement as described below. Control incubations in the absence of added sPLA 2 were carried out in parallel and used to calculate specific hydrolysis.
GC-MS Measurements-The released fatty acids extracted by Dole's procedure were methylated with diazomethane and separated by gas chromatography on a capillary column of Supelcowax-10 bonded phase (0.32 mmx30 m, Supelco) with a Hewlett Packard 5890 Series II gas chromatograph. Fatty acids were detected by mass spectrometry (Nermag 10-10C, France) in the chemical ionization mode with ammonia (0.1 bar) as the reagent gas. The positive quasi-molecular ions were monitored and time-integrated. Quantification referred to an internal standard of heptadecanoic methyl ester with response factors was calculated with the various fatty acid methyl ester calibrators.
RESULTS AND DISCUSSION
Molecular Cloning of hGX sPLA 2 and Chromosomal Localization of Its Gene-Protein sequences of various sPLA 2 s were used to search for related sequences in gene data bases by using the tBLASTn sequence alignment program (62) . As a result, we identified a human EST of 445 bp that was originally obtained from a fetal lung cDNA library (Fig. 1) . The deduced amino acid sequence of the EST displayed a high homology to other sPLA 2 s, including several amino acids invariably conserved in catalytically active sPLA 2 s. We thus postulated that this EST was a partial copy of a mRNA coding for a novel low molecular mass sPLA 2 . This sPLA 2 was assigned as hGX sPLA 2 in accordance with the recent numbering system proposed by Dennis (2) . Two primers were then designed from the EST sequence and used in PCR amplification to screen for the presence of hGX sPLA 2 in human testis, human placenta, and human fetal lung cDNAs. Only human fetal lung cDNAs produced the expected 327-bp PCR fragment predicted from the EST sequence. This fragment was cloned and sequenced, confirming its identity with the EST sequence. This PCR fragment was then used as a probe to hybridize to several human multiple Northern blots to analyze the transcription pattern of hGX sPLA 2 . A 1.5-kb transcript coding for this sPLA 2 was found in spleen, thymus, and peripheral blood leukocytes, while no such expression was observed in several other human tissues, including human fetal lung (see Fig. 5 ). These data indicate that this novel sPLA 2 is expressed at a fairly low level in a limited number of human tissues. This prompted us to request the clone from which the EST sequence was derived at the "I.M.A.G.E. consortium" (LLNL) cDNA clones data base (63) . This clone was found to contain a cDNA insert of 1020 bp bearing an open reading frame of 166 amino acid residues, thus coding for the entire protein sequence of the novel sPLA 2 (Fig.  1) . The 5Ј-noncoding region was found to contain an Alu repetitive element, while the short 3Ј-noncoding region contained a canonical polyadenylation site located 18 bases upstream from a poly(A) tail (Fig. 1) .
After removal of the 5Ј Alu repeat, the cDNA clone was used as a probe to map the hGX sPLA 2 gene by in situ hybridization on human metaphase chromosomes. In the 100 metaphase cells examinated after in situ hybridization, there were 191 silver grains associated with chromosomes and 59 of these (30.9%) were located on chromosome 16. The distribution of grains on this chromosome was not random, since 74.6% (44/59) of them mapped to the p13.1-p12 region of chromosome 16 short arm (Fig. 2) . These results indicate that the hGX sPLA 2 gene maps to the 16p13.1-p12 region of the human genome. The chromosomal localization of this novel sPLA 2 is thus distinct from those of other known sPLA 2 s which have been mapped on chromosomes 1 and 12 (Table I) (40, 70, 71) .
Structural Features of hGX sPLA 2 and Comparison with Other sPLA 2 s-The hGX sPLA 2 cDNA clone predicts a mature sPLA 2 protein of 123 amino acids (calculated molecular mass, 13.6 kDa) and the presence of a signal peptide with a maximal length of 42 amino acids (Fig. 1) . The calculated isoelectric point of the mature protein is 5.29, thus placing hGX sPLA 2 as the most acidic human sPLA 2 (Table I) . Sequence pattern analysis indicates that hGX sPLA 2 contains a potential glycosylation site at position 71, which is also found in the sequence of the mouse group IIC sPLA 2 (Table I and Fig. 3) . Two potential initiator methionines located at positions Ϫ42 and Ϫ32 relative to the mature protein are found in the hGX sPLA 2 sequence (Fig. 1) . Interestingly, two potential initiator methionines were also observed in the mouse group IIC sPLA 2 (39) . Although the second methionine of the hGX sPLA 2 sequence does not appear in a more favorable context for initiation of translation as compared with the first methionine (65), the use of this second methionine as a translation initiation site will reduce the length of the prepropeptide to 32 amino acids, i.e. to a size more consistent with those of other sPLA 2 signal peptide sequences (19, 25, 26, 36, 37, 39) . The presence of an arginine doublet and of other polar residues preceding the mature sPLA 2 protein strongly suggests that the signal sequence of hGX sPLA 2 is a prepropeptide. It was, however, difficult to assign the position of the signal peptidase cleavage site that separates prepeptide and propeptide sequences (72) . In addition, no evident homology was observed between the putative hGX sPLA 2 propeptide sequence and that of other sPLA 2 s containing propeptides (19, 39) . Although the maturation processing of hGX sPLA 2 remains to be elucidated, cleavage at dibasic amino acid motifs, including an arginine doublet, is known to be efficiently catalyzed by subtilisin-like protein convertases in the Golgi apparatus (73), thus suggesting that hGX sPLA 2 might be secreted as an active enzyme after removal of its propeptide sequence into the cell interior.
An alignment of the amino acid sequence of various mammalian sPLA 2 s with the sequence of hGX sPLA 2 is presented in Fig. 3 , and the biological properties of these sPLA 2 s are compared in Table I . Fig. 3 shows that hGX sPLA 2 displays only 27-35% identity with other mammalian sPLA 2 s, indicating no preferential homology with most of the other sPLA 2 s. However, comparison of the complete hGX protein sequence with data bases indicates a slightly higher level of identity with group II sPLA 2 s including those of snake venom origin. For example, hGX sPLA 2 displays 35% identity with human group II sPLA 2 , while only 29% identity is observed with human group I sPLA 2 .
As a hallmark of all other sPLA 2 s, the hGX sPLA 2 protein contains a large number of cysteines that are most probably assembled into disulfide bridges. Of the 16 cysteines found in the structure of hGX sPLA 2 , two are located at positions 11 and 77, which are characteristic of group I sPLA 2 s, while two others are found at positions 50 and 137, which are typical of group II sPLA 2 s (Table I ). The other cysteines are located at positions observed in both group I and II sPLA 2 s, but not at positions that are characteristic of group IIC sPLA 2 s (Fig. 3 and Table I ). This cysteine pattern places the newly cloned sPLA 2 in a novel group, assigned as group X, according to the PLA 2 nomenclature recently refined by Dennis (2) . In fact, the cysteine pattern of hGX sPLA 2 resembles that of PLA 2 L3Ј (Table I ), except that this latter sPLA 2 contains an extra cysteine at position 18 (Fig.  3) . It is also interesting to note that hGX sPLA 2 has an amino acid C-terminal extension, which is characteristic of group II sPLA 2 s, while it contains neither the elapid loop characteristic of group IA nor the pancreatic loop, a particular feature of group IB sPLA 2 s, or the 4 amino acid insertion found in group IIC sPLA 2 s (Table I and Fig. 3) (5) . Fig. 3 also shows that hGX sPLA 2 contains all of the amino acids that are absolutely conserved in active sPLA 2 enzymes, indicating that the newly cloned sPLA 2 could be catalytically active.
A phylogenetic tree was derived from an alignment of all a As determined from the sequence of mature proteins. For PLA 2 L5Ј and PLA 2 L3Ј, the protein mature sequences correspond to those shown in Fig. 3 .
b Refer to Fig. 3 for the position of disulfide bridges.
known protein sequences of mammalian sPLA 2 s (Fig. 4) . A first division was observed in this tree between PLA 2 L3Ј/PLA 2 L5Ј and other mammalian sPLA 2 s, that places these two sPLA 2 domains on a branch distinct from that of other mammalian sPLA 2 s. This is particularly interesting if one considers that these two branches correspond to a separation between catalytically active and inactive sPLA 2 s. Indeed, it is likely that the PLA 2 L3Ј and PLA 2 L5Ј domains (45), if expressed separately as sPLA 2 proteins, would correspond to catalytically inactive enzymes, since these structures do not have several of the residues found in catalytically active sPLA 2 s (Fig. 3) . According to this tree, a second duplication event would have occurred to generate the present group I sPLA 2 s and another branch from which the other mammalian sPLA 2 s originate. Interestingly, hGX sPLA 2 appears to result from an ancestral duplication event occurring after the separation of group I sPLA 2 s and other sPLA 2 s, but before the divergence between group II and group V sPLA 2 s (Fig. 4) . Therefore, it is likely that sPLA 2 s from groups II, V, and X have emerged from a common ancestor, while sPLA 2 s from group I are more distantly related and arose before the development of these more recent groups. This dendrogram is also in accordance with the chromosomal localization of sPLA 2 s (Table I) . Indeed, the three closely related human sPLA 2 s from group IIA, IIC, and V, which would have emerged from recent gene duplication events, map to chromosome 1, while the more distant human group I and human group X sPLA 2 s map to chromosome 12 and 16, respectively. Finally, it appears from this tree that group IIC sPLA 2 s are more distant from group IIA and group V sPLA 2 s that would have emerged from a common ancestor (Fig. 4) . Transcription Pattern of hGX sPLA 2 and Comparison with That of Other Human sPLA 2 s-The tissue expression pattern of hGX sPLA 2 was analyzed by probing several human multiple tissue Northern blots at high stringency (Fig. 5) . Transcripts of 1.5 kb coding for hGX sPLA 2 were detected in adult spleen and at a lower level in adult thymus and peripheral blood leukocytes. This result could indicate a specific expression of hGX sPLA 2 in cells related to the immune system and inflammation. It is then possible that hGX sPLA 2 , as with group II and group V sPLA 2 s (3, 16, 27, 38, 74) , may participate in the release of lipid mediators of inflammation. Whether the expression of hGX sPLA 2 , as with human group II sPLA 2 (3, 16, 27, 74) , is up-regulated in certain pathological conditions remains to be determined. Although the cDNA coding for hGX sPLA 2 was originally cloned from a human fetal lung library, no transcript was detected in human fetal lung, indicating that hGX sPLA 2 is not highly expressed in this fetal tissue (although the absence of expression may also be due to differences in sample preparations from different individuals). No expression was detected in other fetal tissues such as heart, liver, and brain (Fig. 5) . Another low abundance 0.8-kb transcript was detected in the colon, lung, and pancreas, which could result from distinct sites of initiation or termination of transcription or from alternative splicing.
The pattern of expression of hGX sPLA 2 was then compared with those of other human sPLA 2 s. In accordance with previous data (19, 55) , a huge amount of human group I sPLA 2 transcript was detected in adult pancreas and at lower levels in the spleen, lung, and prostate. No detectable expression was observed in the kidney and small intestine, contrasting with previous data (18, 75) . Interestingly, a 0.5-kb transcript was (39) . The level of identity between hGX sPLA 2 and each other sPLA 2 is indicated. The consensus sequence of active sPLA 2 s was refined from that published previously (5). Cysteines that are conserved throughout all sPLA 2 s are indicated in capital letters, while those conserved in some sPLA 2 subgroups are indicated in lower case letters. Note that hPLA 2 L5Ј and hPLA 2 L3Ј do not share some of the active site residues, indicated in the consensus sequence of catalytically active sPLA 2 s, and thus may belong to catalytically inactive enzymes.
FIG. 4.
Phylogenetic tree of mammalian sPLA 2 s. sPLA 2 s sequences were analyzed using the Genetics Computer Group (GCG) package. The phylogenetic tree was generated using successively pileup, distances, and growtree programs. sPLA 2 also observed in the ovary as well as in fetal lung and fetal liver, while a transcript of higher size was detected in the testis (Fig. 5) . Fig. 5 shows that human group II sPLA 2 is widely distributed in several human adult tissues, including heart, liver, skeletal muscle, small intestine, and prostate. As for the human pancreatic sPLA 2 , human group II sPLA 2 is expressed also in fetal liver (Fig. 5) . These results are in accordance with the previous detection of human group II sPLA 2 in a variety of mammalian tissues and cells, although the expression levels might be rather variable, depending on cell activation, which is known to highly modulate the expression of human group II sPLA 2 (3, 16, 27, 29, 75) . For example, no human group II sPLA 2 transcripts are detected in spleen and peripheral blood leukocytes, from which human group II sPLA 2 was characterized (3, 16, 27, 76) . As previously observed (36) , human group V sPLA 2 is strongly expressed in adult heart and at lower levels in the lung and liver (Fig. 5) . A low expression is also observed in the prostate, testis, ovary, small intestine, and colon, while no expression is detected in fetal tissues (Fig. 5) . Taken together, it appears that the tissue distribution of these four human sPLA 2 s is different, suggesting diverse biological functions for each of them. Besides the expression of hGX sPLA 2 in spleen, where both human group I (Fig. 5 ) and human group II sPLA 2 s (76) are also expressed, hGX sPLA 2 is expressed in the thymus, a tissue in which other human sPLA 2 s are not detected (Fig. 5) . The presence of a secretory PLA 2 activity in the thymus either at adult stages or during the fetal thymic development is not well documented. Group II sPLA 2 is known to be strongly expressed in rat thymus after endotoxic shock induced by lipopolysaccharides (77) , and PLA 2 activity has been detected in T lymphocytes and epithelial cells from rat thymus, P-labeled insert of hGX sPLA 2 (hGX probe) as described under "Experimental Procedures." Sk. muscle, skeletal muscle; PBL, peripheral blood leukocytes. The same blots were then hybridized at high stringency successively with the entire coding sequences of human group II sPLA 2 (hGII probe), human group V sPLA 2 (hGV probe), and human group I sPLA 2 (hGI probe). Filters were exposed for 7 days for each panel except for hybridization of human group I sPLA 2 to pancreas (3 h of exposure). The same blots were finally hybridized with the commercial ␤-actin probe (7 h of exposure). but the molecular nature of these PLA 2 s has not been identified (78, 79) . The biological role of PLA 2 activity in thymus is poorly understood, although certain reports suggest a role in rat thymocyte apoptosis (80, 81) . Interestingly, p-bromophenacyl bromide, a known inhibitor of sPLA 2 s (14, 30, 82, 83) , prevents apoptosis of rat thymocytes and lymphoma cells (84) .
Recombinant Expression of hGX sPLA 2 and Characterization of sPLA 2 Activity-To test whether the hGX sPLA 2 cDNA really encodes a catalytically active sPLA 2 , this cDNA was inserted into the expression vector pcDNA I and then transfected into eukaryotic cells. Three different constructs of hGX sPLA 2 were prepared. The first construct was generated by insertion of the full-length cDNA clone (1020 bp) into the expression vector. Two other constructs were prepared by a PCR-assisted strategy to insert into the expression vector only the cDNA sequence coding for the mature protein preceded by the prepropeptide sequence, starting either at methionine-42 (Met-42 construct) or at methionine-32 (Met-32 construct). In addition, a consensus site for initiation of translation was inserted in both of these latter constructs to increase the efficiency of expression of hGX sPLA 2 (65) . The three different constructs were transfected into COS cells, and the cell supernatants were assayed for sPLA 2 activity at different times after transfection (Fig. 6 ). Cell supernatants from COS cells transfected with the three different constructs accumulated hGX sPLA 2 activity, whereas cells transfected with the parent vector did not show sPLA 2 activity (Fig. 6A) . A sPLA 2 activity representing 6% of the total cellular activity was recovered from the cell lysate obtained 72 h after cell transfection, indicating that hGX sPLA 2 was actively secreted by COS cells (Fig. 6A ). The expression level of hGX sPLA 2 activity obtained with Met-42 and Met-32 clones was about 10-fold higher relative to that observed with the full-length cDNA construct, probably due to the presence of the consensus leader sequence added in the PCRmade constructs (Fig. 6 ). Furthermore, the expression level of sPLA 2 activity was not significantly modified when the translation of hGX sPLA 2 started at methionine-32, suggesting that this methionine may be functional in vivo as an initiator site of translation. Finally, based on the presence of a propeptide sequence ending with an arginine doublet in the structure of hGX sPLA 2 , it was of interest to verify whether hGX sPLA 2 could be secreted as a zymogen. For that purpose, COS cells were transfected and transferred into serum-free medium, and the resulting supernatants were treated with trypsin and then assayed for sPLA 2 activity. Treatment with trypsin (which is assumed to cleave efficiently at the propeptide arginine doublet if present) did not significantly increase the supernatant sPLA 2 activity, suggesting that most of the sPLA 2 released into the cell incubation medium was already active and thus that the cleavage of the propeptide sequence might have already occurred during the cell maturation of hGX sPLA 2 . When human HEK 293 cells were used instead of COS cells for the same experiments, similar results were obtained, suggesting that hGX sPLA 2 is an active enzyme efficiently secreted by diverse eukaryotic cells (data not shown). As shown in Fig. 6 , B and C, recombinant sPLA 2 required 10 mM Ca 2ϩ for maximal enzymatic activity and was optimally active at physiological pH, with a rapid drop in sPLA 2 activity observed below pH 6.0 and above pH 8.0.
The substrate preference of hGX sPLA 2 was determined using as substrate artificial liposomes of natural lipids as well as erythrocyte ghost membranes. Table II indicates that hGX sPLA 2 hydrolyzes phosphatidylethanolamine slightly more efficiently than phosphatidylcholine, while phosphatidylserine is poorly hydrolyzed. This substrate preference is very similar to that known for other sPLA 2 s (14, (25) (26) (27) 30) . The results presented in Table II also indicate that hGX sPLA 2 hydrolyzes more efficiently phospholipids containing polyunsaturated fatty acids at the sn-2 position, whatever the polar head group of phospholipids. This may suggest that hGX sPLA 2 prefers lipids containing polyunsaturated fatty acids. Whether this apparent specificity is preserved for physiological substrates, such as membranes from live cells, remains to be addressed.
In conclusion, this report describes the molecular cloning and the characterization of a novel low molecular mass sPLA 2 . Besides its particular structural features, which assign this sPLA 2 to a new group, the cloned enzyme is expressed in the spleen, thymus, and peripheral blood leukocytes where it may realize particular function(s). While the origin of cells that express this novel sPLA 2 is currently unknown, hGX sPLA 2 expression in the thymus, spleen, and leukocytes strongly suggests a role in relation to the immune system and/or inflammation. In that respect, it will be particularly interesting to analyze the expression of hGX sPLA 2 during fetal thymic development and upon inflammatory challenge. The hGX sPLA 2 gene has been mapped to chromosome 16, in a region that is closely associated with T cell leukemias (85) . Further work is clearly needed to establish the exact physiological function(s) of this new sPLA 2 and to determine whether it has any relevance in disease states. 
